Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima, Toshihiro Fukushima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Katsuhiro Io, Tomoaki Ueda, Takaaki Ono, Kensuke · 2026

Read Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial by Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima, Toshihiro Fukushima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Katsuhiro Io, Tomoaki Ueda, Takaaki Ono, Kensuke (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219402.txt.

Description

Hiroshi Ureshino and colleagues report extended follow-up of the DAVLEC trial, which tested low-dose dasatinib for chronic myeloid leukemia in older patients, in a 2026 letter. Tyrosine kinase inhibitors transformed the leukemia's outlook, but patients over seventy carry heart disease and other medicines, making full-dose treatment risky. The trial gave twenty milligrams daily as first treatment and reports outcomes over years.

Forty-eight patients from the trial, median age seventy-eight, were followed for a median of sixty-eight months. Five-year rates of major molecular response reached 89.3 percent, and more than half achieved the deepest response category. Over half reached major response while staying at or below the twenty-milligram dose. Responding early predicted deeper responses, while male sex predicted shallower ones, and patients starting with more natural killer cells fared better. They present the data as support for dose-optimized treatment in the older group.

Catalog record

CREATORHiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima, Toshihiro Fukushima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Katsuhiro Io, Tomoaki Ueda, Takaaki Ono, Kensuke
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE11 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13219402

Browse the full library · About the Tower of Babel